Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05797896 · ClinicalTrials.gov registry record

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

A clinical trial of Eye Diseases and Geographic Atrophy, sponsored by Complement Therapeutics.

Active
Registry status
250
Enrollment target
20
Study locations

NCT05797896: Active study of Eye Diseases and Geographic Atrophy, sponsored by Complement Therapeutics.

NCT05797896 is a study of Eye Diseases and Geographic Atrophy that is active but no longer recruiting, run by Complement Therapeutics. The registered enrollment target is 250 participants, below the 741,294-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05797896, a study of Eye Diseases and Geographic Atrophy, is active but no longer recruiting, sponsored by Complement Therapeutics.

ACTIVE NOT RECRUITING
Registry status
250 participants
Enrollment target
20
Study locations

Study Summary

An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

Primary Outcome

To assess the correlation between circulating levels of complement proteins measured using the Complement Precision Medicine (CPM) Platform and Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

Study Locations (20)

Other

  • Belfast City Hospital - Belfast
  • Bradford Royal Infirmary - Bradford
  • Frimley Park Hospital - Frimley
  • Gloucestershire Royal Hospital - Gloucester
  • Liverpool Hospital - Liverpool
  • Moorfields Eye Hospital - London
  • Western Eye Hospital - London
  • Manchester Royal Eye Hospital - Manchester
  • Newcastle Hospital - Newcastle
  • Nottingham City Hospital - Nottingham

Texas

  • Retina Research Institute of Texas - Abilene
  • Texas Retina Associates - Plano
  • San Antonio Eye Center - San Antonio

California

  • Global Research Management - Glendale
  • Northern California Retina Vitreous Associates - Mountain View

Indiana

  • Midwest Eye Institute - Carmel

Maryland

  • Mid Atlantic Retina Specialists - Hagerstown

Nevada

  • Sierra Eye Associates - Reno

Oregon

  • Verum Research LLC - Eugene

Pennsylvania

  • Mid Atlantic Retina - Philadelphia

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2023-02-07
Est. Completion 2027-07-31
Complement Therapeutics

3 total trials

What the registry record for NCT05797896 still lists

NCT05797896 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 741,294-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).

The record links to 7 conditions, with Eye Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT05797896 names 20 study sites across 8 states, led by Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT05797896 about?

NCT05797896 is a clinical study titled "Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study". An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

What is the current status of trial NCT05797896?

This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2023-02-07. Estimated completion is 2027-07-31.

What conditions does trial NCT05797896 study?

This clinical trial studies the following conditions: Eye Diseases, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration.

Who is sponsoring clinical trial NCT05797896?

This trial is sponsored by Complement Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05797896 being conducted?

This trial has 20 study locations across California, Indiana, Maryland, Nevada, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eye Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05797896's enrollment target sits among peer trials

250 9th of 27 higher than 19 of 27 other Eye Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05797896, the US trial registry maintained by the National Library of Medicine. NCT05797896 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.